Core Insights - The Shanghai Composite Index decreased by 0.37%, while the CSI Hong Kong-Shanghai-Shenzhen 500 Healthcare Index fell by 1.74%, closing at 8507.96 points with a trading volume of 40.594 billion yuan [1] - Over the past month, the CSI Hong Kong-Shanghai-Shenzhen 500 Healthcare Index has increased by 17.84%, 24.27% over the last three months, and 34.48% year-to-date [1] Index Composition - The CSI Hong Kong-Shanghai-Shenzhen 500 Healthcare Index is composed of 11 industry categories, reflecting the overall performance of different sectors within the index [1] - The top ten holdings in the index are: WuXi AppTec (10.42%), Hengrui Medicine (9.97%), BeiGene (9.63%), Innovent Biologics (6.64%), Mindray Medical (6.06%), WuXi Biologics (5.19%), CanSino Biologics (4.4%), China National Pharmaceutical Group (3.36%), CSPC Pharmaceutical Group (3.17%), and United Imaging Healthcare (2.85%) [1] Market Distribution - The market distribution of the CSI Hong Kong-Shanghai-Shenzhen 500 Healthcare Index shows that the Hong Kong Stock Exchange accounts for 37.87%, the Shanghai Stock Exchange for 33.61%, and the Shenzhen Stock Exchange for 28.52% [2] Sector Allocation - The sector allocation within the index includes: Chemical Drugs (36.20%), Pharmaceutical and Biotechnology Services (18.33%), Biopharmaceuticals (18.14%), Medical Devices (11.07%), Traditional Chinese Medicine (8.56%), and Medical Commerce and Services (7.70%) [2] Index Adjustment - The index samples are adjusted biannually, with adjustments occurring on the next trading day following the second Friday of June and December each year [2] - Weight factors are generally fixed until the next scheduled adjustment, with special circumstances allowing for temporary adjustments [2] Fund Tracking - Public funds tracking the CSI Hong Kong-Shanghai-Shenzhen 500 Healthcare Index include the China Merchants CSI Hong Kong-Shanghai-Shenzhen 500 Healthcare ETF [3]

金十图示：2025年08月01日（周五）富时中国A50指数成分股今日收盘行情一览：银行股走势分化，石油、证券、医药股走软 富时中国A50指数连续 光大银行 2392.96亿市值 6.38亿成交额 4.05 0.00(0.00%) 保险 中国太保 中国平安 中国人保 机械 3608.68亿市值 3569.15亿市值 10598.36亿市值 9.02亿成交额 28.60亿成交额 6.15亿成交额 58.20 37.10 8.16 -0.36(-0.96%) -0.49(-0.83%) -0.02(-0.24%) 酿酒行业 贵州茅台 山西汾酒 五粮液 17800.32亿市值 2182.64亿市值 4696.75亿市值 42.01亿成交额 9.39亿成交额 14.91亿成交额 1417.00 178.91 121.00 -4.67(-0.33%) -0.09(-0.05%) -0.15(-0.12%) 半导体 海光信息 北方华创 寒武纪-U HYGON 2379.85亿市值 2882.85亿市值 3201.78亿市值 49.98亿成交额 18.35亿成交额 31.52亿成交额 329.80 689.10 137.75 ...

Core Insights - The report highlights the significant role of company secretaries (董秘) in connecting investors and listed companies, with a total salary of 4.086 billion yuan for A-share company secretaries in 2024, averaging 754,300 yuan per year [1] Salary Distribution - The salary distribution for company secretaries in the A-share biopharmaceutical sector shows that 32% earn below 500,000 yuan, 41% earn between 500,000 and 1 million yuan, 23% earn between 1 million and 2 million yuan, 3% earn between 2 million and 3 million yuan, and 1% earn above 3 million yuan [5] Age Distribution - The age distribution of company secretaries indicates that 47% are between 40-50 years old, 23% are over 50, 29% are between 30-40, and only 1% are under 30, with the youngest being 28 years old [1] Educational Background - The educational background of company secretaries shows that 4% have an associate degree, 42% hold a bachelor's degree, 50% have a master's degree, and 4% possess a doctoral degree, with over half holding a master's degree or higher [3] Investor Engagement - There is a significant variance in the number of investor meetings held by companies, with 32% of companies hosting fewer than 10 meetings per year, while only 1% have more than 1,000 meetings [9] Top Earning Company Secretaries - The top five highest-paid company secretaries have salaries ranging from 325.65 million yuan to 738.76 million yuan, with the youngest among them being 32 years old and having just started in the role [7]

Core Insights - The report highlights that the total salary of A-share listed company secretaries reached 4.086 billion yuan in 2024, with an average annual salary of 754,300 yuan [1] - Over 21% of the secretaries earn more than 1 million yuan annually, indicating a significant compensation level in the industry [1] Salary Distribution - The salary distribution among secretaries in the biopharmaceutical sector shows that 32% earn below 500,000 yuan, 41% earn between 500,000 and 1 million yuan, 23% earn between 1 million and 2 million yuan, 3% earn between 2 million and 3 million yuan, and 1% earn above 3 million yuan [5] - Five secretaries with salaries exceeding 3 million yuan include Li Wenmei from Mindray Medical (7.3876 million yuan), Jiang Yueheng from Yifang Bio (5.2065 million yuan), and others, with the youngest being 32 years old [7] Age and Educational Background - The age distribution of secretaries shows that those aged 40-50 constitute 47%, while those over 50 account for 23%, and those aged 30-40 make up 29%. Secretaries under 30 represent 1% [1] - In terms of educational qualifications, 4% have an associate degree, 42% hold a bachelor's degree, 50% possess a master's degree, and 4% have a doctoral degree, with over half holding a master's degree or higher [3] Investor Engagement - There is a significant variance in the number of investor meetings held by companies, with 32% of companies hosting fewer than 10 meetings annually, while only 1% have more than 1,000 meetings [9] - The top five companies with the most investor meetings include Sanofi Biologics and others, with meeting counts ranging from 1,107 to 2,661 [10]

从CFO的学历分布看，拥有高中、中职、专科、本科、硕士、博士的CFO数量分别为1人、2人、37人、 271人、178人和8人。其中，本科、硕士学历CFO占比最高，合计占比超90%。三名学历最低的CFO分 别为海森药业的潘爱娟（高中）、千金药业的彭意花（中职）、盘龙药业的祝凤鸣（中职）。 专题：专题|2024年度A股CFO数据报告：美的集团钟铮年薪946万，比亚迪周亚琳896万 作为上市公司核心管理层关键成员，财务总监CFO的地位与作用至关重要。新浪财经《2024年度A股 CFO数据报告》显示，2024年A股上市公司财务总监CFO群体薪酬规模合计达42.70亿元，平均年薪为 81.48万元。 分行业来看，统计数据显示，A股共有494家上市医药生物公司，CFO聘任总体情况如下（部分统计口 径剔除无效数据）。 从CFO的年龄分布来看，介于40-50岁的CFO是市场的中坚力量，占比达到51%；50岁以上的CFO占比 为33%；30-40岁的CFO群体占比为15%；年龄小于或等于30岁的CFO数量最少，仅3人，分别为博迅生 物的金曼（29岁）、天益医疗的邵科杰（30岁）、*ST四环的赵洁（30岁）。其中，赵洁于2024 ...

-0.02(-0.35%) +0.09(+0.80%) +0.03(+0.37%) 光大银行 2392.96亿市值 3.88亿成交额 4.05 0.00(0.00%) 得經 中国太保 中国平安 中国人保 0 3626.37亿市值 10660.27亿市值 3615.32亿市值 4.24亿成交额 13.91亿成交额 3.56亿成交额 58.54 37.58 8.20 +0.12(+0.32%) -0.15(-0.26%) +0.02(+0.24%) 酿酒行业 贵州茅台 山西汾酒 五粮液 17807.86亿市值 2176.17亿市值 4692.86亿市值 25.26亿成交额 8.45亿成交额 5.58亿成交额 1417.60 178.38 120.90 -0.62(-0.35%) -4.07(-0.29%) -0.25(-0.21%) 半导体 北方华创 寒武纪-U 海光信息 HYGON 2381.29亿市值 2907.41亿市值 3220.14亿市值 12.26亿成交额 30.95亿成交额 21.51亿成交额 138.54 330.00 694.97 -5.20(-1.55%) -14.53(-2.05%) -0. ...

Core Viewpoint - The performance of the China Securities Guangdong-Hong Kong-Macao Greater Bay Area Development Theme Index and its related ETF shows positive growth trends, indicating potential investment opportunities in the region's market [1][2][3]. Performance Summary - As of August 1, 2025, the index rose by 0.29%, with notable increases in constituent stocks such as Jiejia Weichuang (19.98%) and Shenzhen Sanda A (6.57%) [1]. - The Greater Bay Area ETF (512970) increased by 0.70%, with a recent price of 1.3 yuan, and has shown a cumulative increase of 1.26% over the past two weeks [1]. - Over the past year, the ETF's net value has risen by 27.00%, with a maximum monthly return of 21.99% since its inception [1][2]. Liquidity and Trading Activity - The ETF had a turnover rate of 0.01% during the trading session, with a transaction volume of 5176.00 yuan [1]. - The average daily trading volume over the past year was 256,000 yuan [1]. Risk and Return Metrics - The ETF's Sharpe ratio for the past month was 2.25, indicating strong risk-adjusted returns [2]. - Year-to-date, the ETF has experienced a relative drawdown of 0.43% compared to its benchmark, with a recovery period of 108 days [2]. Tracking Accuracy - The tracking error of the ETF year-to-date is 0.053%, demonstrating its close alignment with the underlying index [3]. - The index reflects the performance of companies benefiting from the development of the Guangdong-Hong Kong-Macao Greater Bay Area, including a selection of up to 50 Hong Kong stocks and 300 companies from the mainland [3]. Top Holdings - As of July 31, 2025, the top ten weighted stocks in the index accounted for 50.37%, with major companies including China Ping An, BYD, and China Merchants Bank [4][6]. - The weightings of the top stocks are as follows: BYD (8.59%), China Ping An (8.55%), and China Merchants Bank (8.14%) [6].

经济观察网天眼查APP显示，近日，深圳迈瑞生物医疗电子股份有限公司申请的"一种定位装置和定位 方法"专利公布。 摘要显示，一种定位装置和定位方法，定位装置包括：至少一个基站，至少三个标签，以及处理器；至 少三个所述标签以不在一条直线上的方式设置于待定位部件；至少一个所述基站用于向至少三个所述标 签中的每个标签发射信号并接收由该标签返回的信号；所述处理器用于：基于至少一个所述基站向至少 三个所述标签中的每个标签发射的信号以及该标签所返回的信号，计算至少三个所述标签中的每个标签 与至少一个所述基站的相对位置信息；基于至少三个所述标签中的每个标签与至少一个所述基站的相对 位置信息计算所述待定位部件的姿态信息。本申请提供了一种新的获取待定位部件的姿态信息的方案。 ...

科创创业ETF（588360）业绩比较基准为中证科创创业50指数收益率，管理人为国泰基金管理有限公 司，基金经理为黄岳，成立（2021-06-29）以来回报为-33.50%，近一个月回报为9.17%。 来源：新浪基金∞工作室 8月1日，科创创业ETF（588360）开盘跌0.30%，报0.663元。科创创业ETF（588360）重仓股方面，宁 德时代开盘涨0.07%，中芯国际跌0.34%，迈瑞医疗跌0.09%，海光信息涨0.36%，中际旭创跌2.34%，新 易盛跌2.15%，寒武纪跌1.34%，汇川技术涨0.14%，阳光电源涨0.04%，澜起科技涨0.09%。 风险提示：市场有风险，投资需谨慎。本文为AI大模型自动发布，任何在本文出现的信息（包括但不 限于个股、评论、预测、图表、指标、理论、任何形式的表述等）均只作为参考，不构成个人投资建 议。 ...

Investment Rating - The report maintains an "Outperform" rating for multiple leading innovative drug companies and CXOs in the healthcare sector [2]. Core Insights - The report emphasizes a sustained positive outlook on the innovative drug industry and its supply chain, highlighting the importance of increasing allocations to leading companies in this space [4][6]. - The performance of the Hong Kong stock picks portfolio showed an average increase of 27.1% in July 2025, outperforming the Hang Seng Healthcare Index, which rose by 22.8% [5][9]. - Major business development (BD) and merger & acquisition (M&A) activities in the innovative drug sector are ongoing, with significant deals reported, indicating a robust market environment [6][35][36]. Summary by Sections Investment Focus - The report lists several companies with an "Outperform" rating, including 恒瑞医药 (Hengrui Pharmaceuticals), 迈瑞医疗 (Mindray), 药明康德 (WuXi AppTec), and others [2]. Performance Analysis - The July 2025 Hong Kong stock picks portfolio included companies like 信达生物 (Innovent Biologics) and 百济神州 (BeiGene), with top performers showing significant gains, such as 映恩生物 (DualityBio) at +48.0% [5][10]. - The healthcare sector in Hong Kong saw notable gains, with companies like 华检医疗 (IVD Medical) and 加科思-B (Jacobio Pharmaceuticals) leading the way [6][34]. Market Trends - The report highlights a recovery in the global innovative drug sector, with leading CXO firms like 药明合联 (WuXi XDC) and 药明康德 (WuXi AppTec) reporting strong earnings growth [7][37]. - Optimized centralized procurement policies and steady progress in innovative drug reimbursement are noted, with over 100 drugs applying for inclusion in the innovative drug reimbursement list [7][38][39]. Company-Specific Insights - 石药集团 (CSPC) and 中国生物制药 (Sino Biopharmaceutical) are newly added to the top picks, with strong potential in their respective innovative drug pipelines [4][32]. - The report discusses the promising clinical pipelines of companies like 三生制药 (3SBio) and 信达生物 (Innovent Biologics), indicating robust growth prospects [18][23].